Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 14/20 | 1.00 |
| ▸ | EGFR | P00533 | 4/20 | 0.54 |
| ▸ | FGFR1 | P11362 | 6/20 | 0.47 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.47 |
| ▸ | FGFR3 | P22607 | 4/20 | 0.47 |
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22781368 | 0.92 | FGFR4 (0.85) | FGFR4EGFRFGFR1FGFR2FGFR3 | |
| SCHEMBL15412791 | 0.82 | FGFR4 (0.69) | FGFR4FGFR1FGFR2FGFR3RPS6KB2 | |
| SCHEMBL29385382 | 0.82 | FGFR4 (0.69) | FGFR4FGFR1FGFR2FGFR3RPS6KB2 | |
| SCHEMBL16683513 | 0.81 | FGFR4 (0.67) | FGFR4FGFR1FGFR2FGFR3RPS6KB2 | |
| SCHEMBL16676911 | 0.80 | FGFR4 (0.66) | FGFR4FGFR1FGFR2FGFR3RPS6KB2 | |
| SCHEMBL16674626 | 0.77 | FGFR4 (0.63) | FGFR4FGFR1FGFR2FGFR3RPS6KB2 | |
| SCHEMBL15618399 | 0.77 | FGFR4 (0.63) | FGFR4FGFR1FGFR2FGFR3RPS6KB2 | |
| SCHEMBL28495534 | 0.77 | FGFR4 (0.62) | FGFR4FGFR1FGFR2FGFR3RPS6KB2 | |
| SCHEMBL28158032 | 0.75 | EGFR (0.76) | FGFR4EGFRPIK3CDPIK3CA | |
| SCHEMBL21154002 | 0.75 | FGFR4 (0.60) | FGFR4FGFR1FGFR2FGFR3RPS6KB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114057700-B | Crystal forms of fibroblast growth factor receptor inhibitor and preparation method thereof | 药捷安康(南京)科技股份有限公司 | 2024-04-19 | — | — | CN | disclosed |
| US-20240043408-A1 | CRYSTAL FORM OF FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITOR AND PREPARATION METHOD THEREFOR | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2024-02-08 | — | — | US | disclosed |
| EP-4190775-A1 | CRYSTAL FORM OF FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITOR AND PREPARATION METHOD THEREFOR | Transthera Sciences (Nanjing), Inc. (CN) | 2023-06-07 | — | — | EP | disclosed |
| WO-2022194160-A1 | SOLID FORM OF FISOGATINIB AND PREPARATION METHOD THEREFOR | 上海启晟合研医药科技有限公司 | 2022-09-22 | — | — | WO | disclosed |
| WO-2022075482-A1 | MEDICINE FOR TREATING CANCER | 株式会社カイオム・バイオサイエンス | 2022-04-14 | — | — | WO | disclosed |
| CN-114057700-A | Crystal form of fibroblast growth factor receptor inhibitor and preparation method thereof | 药捷安康(南京)科技股份有限公司 | 2022-02-18 | — | — | CN | disclosed |
| WO-2022022735-A1 | CRYSTAL FORM OF FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITOR AND PREPARATION METHOD THEREFOR | 药捷安康(南京)科技股份有限公司 | 2022-02-03 | — | — | WO | disclosed |
| EP-3508482-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR AND USE THEREOF | Nanjing Transthera Biosciences Co. Ltd. (CN) | 2019-07-10 | — | — | EP | disclosed |
| CN-107793395-A | Fibroblast growth factor acceptor inhibitor and application thereof | 南京药捷安康生物科技有限公司 | 2018-03-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043408-A1 | CRYSTAL FORM OF FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITOR AND PREPARATION METHOD THEREFOR | FGF2, FGFR1, FGF1 | FGFR4 8/4885EGFR 19/4885FGFR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.